Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Asda underlying profit jumps 24% in 2023

(Sharecast News) - Asda reported a jump in full-year underlying profit and sales on Monday as it continued to lower prices. Adjusted earnings before interest, tax, depreciation and amortisation rose 24% from 2022 to £1.1bn, with like-for-like sales up 5.4% and total sales excluding fuel 7.1% higher at £21.9bn.

The supermarket retailer said growth was driven by its "continued focus on value for customers, and the impact of strategic acquisitions".

During the year, it cut prices on more than 800 popular everyday products, maintaining its position as the lowest-priced traditional supermarket.

Co-owner Mohsin Issa said: "As well as investing in price to maintain our position as the cheapest traditional supermarket, we continued to invest in further enhancing the quality of our products, building on the earlier successful launch of the budget-friendly Just Essentials brand with a significant own-label transformation programme.

"This saw us launch thousands of new and improved food lines to drive quality perception among consumers, including a refresh of our entire ready meals range.

"This investment includes non-food and saw George maintain its market leadership position in back-to-school wear and deliver total clothing sales growth of 3.4% last year - helped by our ongoing focus on price, quality and style."

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.